EHR to EDC Integration

It has been a long-standing industry challenge that 50-70% of data collected in EDC is being manually re-entered from EHR systems by site staff who would rather spend their time on patient care and patient safety. As a result of the need for duplicative data entry, nearly 20-25% of study costs are related to manual transcription, often adding up to three minutes per data point (on data entry, validation, correction). This leads to an average loss of $8 million per day. Powered by Cerner, Oracle is working to transform the way that healthcare data is transferred to clinical trial systems for clinical research. By intelligently extract healthcare data from EHR systems to fuel clinical trials, Oracle is focused on creating a seamless experience for life sciences stakeholders.

• Jeyaseelan Jeyaraj (Jey)

  Senior Director, Solutions Consulting, Asia Pacific,
  Oracle Life Sciences

Artificial Intelligence in Pharmacovigilance (or) Use of technology in Pharmacovigilance

Application of Artificial Intelligence in pharmacovigilance means new methods to improve case management and monitoring the risk-benefit balance. AI is interesting whenever you want to automate repetitive tasks involved in Data Processing. AI also help you to identify situations similar to your current case that may suggest a potential signal. There are various Pharmacovigilance activities where AI can be useful: First: Identification of unreported cases by browsing Social Media. Secondly, Individual Case Safety Report (ICSR). From a quantitative stand point this is clearly the most important step, because AI can increase speed and quality of processing. However, from a value, AI can assist Signal Detection. Risk Management is clearly a key element where AI can improve your work.

• Dr. Rajendra Kumar Kasi

  Vice-President and Global Head of Pharmacovigilance,
  Glenmark Pharmaceuticals Limited

Turn the Corner

• Edsel Pereira

  Executive Vice President - Information Technology,
  Glenmark Pharmaceuticals Limited

Improving Patient Recruitment with the Learning Health Network

Inefficiencies in patient recruitment continue to be a prevalent challenge in clinical research and significantly impact all stakeholders of the life sciences industry. Approximately $1.9 billion is spent on recruitment annually and 48% of research sites enroll one or fewer patients for a given trial. Oftentimes, 72% of trial participants are already patients at the site and 28% are new patients. Strong site relationships, deep clinical research expertise, and robust technology is key to achieving better study feasibility and high confidence in the eligibility of enrolled participants.

• Jeyaseelan Jeyaraj (Jey)

  Senior Director, Solutions Consulting, Asia Pacific,
  Oracle Life Sciences

NextGen Safety One

Oracle's Safety One Strategy, offerings and differentiators including how we are building an open, intelligent, cloud-based health platform with secure applications.

• Firasatullah Syed

  Principal Solutions Consultant, Oracle Life Sciences